drugset
drugset / Trial / NCT02905253

A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

NCT02905253 ↗

Phase 1 Terminated 56 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedParallel-groupTriple-blindOther

Summary

The primary purpose of this first-in-man study is to investigate whether AC-084 is safe and well-tolerated when orally administered at single- and multiple-ascending dose to healthy adults

Timeline

Start
2016-09-12
Primary completion
2017-12-10
Completion
2017-12-10

Outcome

Outcome not reported

Stopped (Enrollment): “The study has been terminated due to difficulties in recruiting subjects into Part C. No safety concerns contributed to the termination of the study”

Drugs

EvaluationDrugModalityDoseRoute
Subject AC-084 Unknown 1 mg Oral
Subject AC-084 Unknown 10 mg Oral
Subject AC-084 Unknown 100 mg Oral

Indications

No indication recorded.